Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Net Income towards Common Stockholders of -$92.3 million for Q1 2026, down 26.0% year-over-year from -$124.7 million in Q1 2025, and down 57.89% on a QoQ basis from -$58.4 million in Q4 2025.
Madrigal Pharmaceuticals (MDGL) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$92.3 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 26.0% year-over-year to -$92.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$304.1 million (up 22.35% YoY) and the FY2025 annual result came in at -$285.0 million, up 38.82% from the prior year.
- Net Income towards Common Stockholders eased to -$92.3 million in Q1 2026 per MDGL's latest filing, from -$58.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$42.2 million in Q2 2025 and bottomed at -$152.0 million in Q2 2024.
- The 5-year median for Net Income towards Common Stockholders is -$85.8 million (2023), against an average of -$89.0 million.
- The widest annual swing landed in 2024, when Net Income towards Common Stockholders tumbled 91.87%; it then jumped 72.21% in 2025.
- Tracing MDGL's Net Income towards Common Stockholders over 5 years: stood at -$85.9 million in 2022, then slumped by 30.6% to -$112.2 million in 2023, then soared by 47.04% to -$59.4 million in 2024, then advanced by 1.63% to -$58.4 million in 2025, then slumped by 57.89% to -$92.3 million in 2026.
- Per Business Quant, the three latest MDGL Net Income towards Common Stockholders figures stand at -$92.3 million (Q1 2026), -$58.4 million (Q4 2025), and -$111.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Madrigal Pharmaceuticals | 14.44 Bn | 14.20 Bn | - | -92.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.28 Mn |
| Dec 31, 2025 | -58.45 Mn |
| Sep 30, 2025 | -111.12 Mn |
| Jun 30, 2025 | -42.24 Mn |
| Mar 31, 2025 | -73.24 Mn |
| Dec 31, 2024 | -59.42 Mn |
| Sep 30, 2024 | -106.96 Mn |
| Jun 30, 2024 | -151.97 Mn |
| Mar 31, 2024 | -147.54 Mn |
| Dec 31, 2023 | -112.19 Mn |
| Sep 30, 2023 | -98.74 Mn |
| Jun 30, 2023 | -85.80 Mn |
| Mar 31, 2023 | -76.90 Mn |
| Dec 31, 2022 | -85.91 Mn |
| Sep 30, 2022 | -81.20 Mn |
| Jun 30, 2022 | -70.73 Mn |
| Mar 31, 2022 | -57.52 Mn |
| Dec 31, 2021 | -64.55 Mn |
| Sep 30, 2021 | -63.10 Mn |
| Jun 30, 2021 | -61.65 Mn |
| Mar 31, 2021 | -52.82 Mn |
| Dec 31, 2020 | -59.12 Mn |
| Sep 30, 2020 | -57.96 Mn |
| Jun 30, 2020 | -49.12 Mn |
| Mar 31, 2020 | -36.14 Mn |
| Dec 31, 2019 | -27.74 Mn |
| Sep 30, 2019 | -21.43 Mn |
| Jun 30, 2019 | -19.70 Mn |
| Mar 31, 2019 | -15.08 Mn |
| Dec 31, 2018 | -11.48 Mn |
| Sep 30, 2018 | -8.51 Mn |
| Jun 30, 2018 | -6.66 Mn |
| Mar 31, 2018 | -6.36 Mn |
| Dec 31, 2017 | -8.45 Mn |
| Sep 30, 2017 | -8.36 Mn |
| Jun 30, 2017 | -8.35 Mn |
| Mar 31, 2017 | -6.00 Mn |
| Dec 31, 2016 | -7.75 Mn |
| Sep 30, 2016 | -14.05 Mn |
| Jun 30, 2016 | -2.88 Mn |
| Mar 31, 2016 | -1.71 Mn |
| Dec 31, 2015 | -10.54 Mn |
| Sep 30, 2015 | -1.80 Mn |
| Jun 30, 2015 | -19.80 Mn |
| Mar 31, 2015 | -20.71 Mn |
| Dec 31, 2014 | -20.35 Mn |
| Sep 30, 2014 | -19.97 Mn |
| Jun 30, 2014 | -22.29 Mn |
| Mar 31, 2014 | -23.56 Mn |
| Dec 31, 2013 | -24.16 Mn |
| Sep 30, 2013 | -22.52 Mn |
| Jun 30, 2013 | -22.79 Mn |
| Mar 31, 2013 | -20.73 Mn |
| Dec 31, 2012 | -18.12 Mn |
| Sep 30, 2012 | -15.00 Mn |
| Jun 30, 2012 | -14.62 Mn |
| Mar 31, 2012 | -15.05 Mn |
| Dec 31, 2011 | -10.74 Mn |
| Sep 30, 2011 | -12.73 Mn |
| Jun 30, 2011 | -12.50 Mn |
| Mar 31, 2011 | -11.40 Mn |
| Dec 31, 2010 | -8.82 Mn |
| Sep 30, 2010 | -10.26 Mn |
| Jun 30, 2010 | -9.07 Mn |